Arcutis Biotherapeutics (ARQT) Institutional Ownership

Of the 248 institutional investors that purchased Arcutis Biotherapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Rubric Capital Management LP ($3.46M), Suvretta Capital Management LLC ($2.88M), Perpetual Ltd ($2.02M), Jennison Associates LLC ($1.91M), Point72 Asset Management L.P. ($1.75M), Candriam S.C.A. ($1.59M), and Paradigm Biocapital Advisors LP ($1.47M).

Institutional investors have bought a total of 27,401,748 shares in the last 24 months. This purchase volume represents approximately $654.85M in transactions.

Of the 94 institutional investors that sold Arcutis Biotherapeutics' stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Jennison Associates LLC ($7.52M), Rubric Capital Management LP ($2.70M), Invesco Ltd. ($1.23M), Perpetual Ltd ($1.11M), Suvretta Capital Management LLC ($1.06M), JPMorgan Chase & Co. ($895.99K), and Franklin Resources Inc. ($861.68K).

Institutional investors have sold a total of 23,677,157 shares in the last 24 months. This volume of shares sold represents approximately $575.35M in transactions.